New study tracks ilaris use in rare inflammatory diseases across europe

This study looks at how patients with Familial Mediterranean Fever (FMF) and Still's disease (including systemic juvenile idiopathic arthritis and adult-onset Still's disease) use the drug canakinumab (Ilaris) over the long term. Researchers will track 160 patients across Europe and Israel who have taken canakinumab for at least 6 months to see how well it controls their disease and whether they can reduce other medications like steroids. The goal is to better understand real-world treatment patterns and outcomes.